Dr. Agarwal's Health Care Intrinsic Value

Dr. Agarwal's Health Care intrinsic value. Dr. Agarwal's Health Care (AGARWALEYE) median intrinsic value is ₹855.00 from 9 valuation models (range ₹166–₹1383), vs current price ₹553.10 — +54.6% upside (Trading Below Calculated Value), margin of safety 35.3%. For current market price and key ratios, visit AGARWALEYE stock price BSE.

Market Price (CMP)
₹553.10
Primary Intrinsic Value
₹165.93
Market Cap
₹1770 Cr
+54.6% Upside
Median Value
₹855.00
Value Range
₹166 - ₹1383
Assessment
Trading Below Calculated Value
Safety Margin
35.3%

AGARWALEYE Valuation Methods Summary — DCF, Graham Number & P/E

Dr. Agarwal's Health Care intrinsic value across 9 models vs current price ₹553.10 — upside/downside and value range per method. Browse Dr. Agarwal's Health Care annual reports for revenue, profit, balance sheet and cash flow data.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹165.93 ₹132.74 - ₹199.12 -70.0% EPS: ₹6.60, Sector P/E: 22x
Book Value Method asset ₹1325.00 ₹1192.50 - ₹1457.50 +139.6% Book Value/Share: ₹662.50, P/B: 2.0x
Revenue Multiple Method revenue ₹1106.20 ₹995.58 - ₹1216.82 +100.0% Revenue/Share: ₹831.25, P/S: 2.0x
EBITDA Multiple Method earnings ₹1106.20 ₹995.58 - ₹1216.82 +100.0% EBITDA: ₹744.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹1382.75 ₹1106.20 - ₹1659.30 +150.0% CF Growth: 15.0%, Discount: 15%
PEG Ratio Method growth ₹165.93 ₹149.34 - ₹182.52 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹165.93 ₹149.34 - ₹182.52 -70.0% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹855.00 ₹769.50 - ₹940.50 +54.6% ROE: 10.8%, P/E Multiple: 12x
Graham Defensive Method conservative ₹313.66 ₹282.29 - ₹345.03 -43.3% EPS: ₹6.60, BVPS: ₹662.50
Method Types: Earnings Asset DCF Growth Dividend Conservative

AGARWALEYE Intrinsic Value vs Market Price — All Valuation Models

Dr. Agarwal's Health Care fair value range ₹166–₹1383 vs current market price ₹553.10 across 9 valuation models. Analyse Dr. Agarwal's Health Care ownership structure to track promoter, FII and institutional holdings.

AGARWALEYE Intrinsic Value Analysis — Undervalued or Overvalued?

Dr. Agarwal's Health Care median intrinsic value ₹855.00, current price ₹553.10 — Trading Below Calculated Value by 54.6%, margin of safety 35.3%.

What is the intrinsic value of AGARWALEYE?

Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Dr. Agarwal's Health Care (AGARWALEYE) is ₹855.00 (median value). With the current market price of ₹553.10, this represents a +54.6% variance from our estimated fair value.

The valuation range spans from ₹165.93 to ₹1382.75, indicating ₹165.93 - ₹1382.75.

Is AGARWALEYE undervalued or overvalued?

Based on our multi-method analysis, Dr. Agarwal's Health Care (AGARWALEYE) appears to be trading below calculated value by approximately 54.6%.

AGARWALEYE Financial Health — Key Ratios vs Industry Benchmarks

Dr. Agarwal's Health Care financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 10.8% Industry Standard: 15%+ Above 10% Measures shareholder return efficiency
Operating Margin 27.0% Industry Standard: 20%+ Above 20% Indicates operational efficiency level
Asset Turnover Ratio 0.67x Industry Standard: 1.0x+ Above 0.5x Measures asset utilization efficiency

AGARWALEYE Cash Flow Quality — Operating & Free Cash Flow

Dr. Agarwal's Health Care operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹519 Cr ₹365 Cr Positive Free Cash Flow 8/10
March 2025 ₹357 Cr ₹-18 Cr Positive Operating Cash Flow 6/10
March 2024 ₹346 Cr ₹-111 Cr Positive Operating Cash Flow 6/10
March 2023 ₹233 Cr ₹-22 Cr Positive Operating Cash Flow 6/10
March 2022 ₹164 Cr ₹87 Cr Positive Free Cash Flow 8/10